NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
Clinical Trials
16 trialsNCT05388058 2026-01-16
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Mayo Clinic
Phase 2 Completed
NCT06731894 2025-12-05
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
City of Hope Medical Center
Phase 2 Recruiting
NCT07167446 2025-10-22
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
Fox Chase Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05836857 2025-10-14
The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study
M.D. Anderson Cancer Center
Active not recruiting
NCT03948074 2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2 Completed
NCT06538389 2025-08-29
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT04482244 2025-07-29
RCT of CBD for Anxiety in Advanced Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04754399 2025-05-09
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT05672342 2024-08-09
Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
City of Hope Medical Center
Phase EARLY_PHASE1 Withdrawn
NCT06518434 2024-07-24
CanHep
University Medical Center Groningen
Phase 2 Recruiting
NCT04585841 2023-07-24
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
University of Copenhagen
Phase 1 Completed
NCT04447846 2023-05-25
Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT02332655 2022-03-02
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 1/2 Completed
NCT05016349 2021-08-23
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
Kafrelsheikh University
Phase 3 Unknown
NCT02255292 2014-10-02
A Study: Pure CBD as Single-agent for Solid Tumor.
Hadassah Medical Organization
Phase 2 Unknown